Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Cardinal Health Inc    CAH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Cardinal Health to Buy Medical-Supplies Provider AssuraMed for $2.07 Billion

02/14/2013 | 08:08am US/Eastern
   By Melodie Warner 
 

Cardinal Health Inc. (>> Cardinal Health, Inc.) agreed to acquire closely held medical-supplies provider AssuraMed for $2.07 billion as the drug wholesaler looks to diversify its offerings.

AssuraMed currently serves more than one million patients nationally with more than 30,000 products. The company bought Invacare Corp.'s (>> Invacare Corporation) domestic medical supplies business for $150 million last month. Including that business, Cardinal Heath said AssuraMed had 2012 revenue of $1 billion.

After the transaction is complete, Cardinal Health will supply ostomy, diabetes, insulin therapy, urological, wound care and incontinence products to the home-healthcare market.

"This is a platform opportunity for Cardinal Health products and services which will be increasingly important as the delivery of care migrates to more cost-effective settings," said Chairman and Chief Executive George Barrett.

Cardinal Health expects AssuraMed to add two cents to three cents a share to its fiscal 2013 adjusted earnings, assuming the deal closes by early April.

The company also estimates its will boost fiscal 2014 adjusted earnings by at least 18 cents a share.

Cardinal has previously disclosed the loss of its contract with pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) to rival AmerisourceBergen Corp. (>> AmerisourceBergen Corp.). Two of Cardinal's huge drug-distribution customers, Walgreen Co. (>> Walgreen Company) and CVS Caremark Corp. (>> CVS Caremark Corporation), have contracts set to end this summer.

The company earlier this month reported its fiscal second-quarter earnings rose 16% as improved margins helped to offset weaker revenue at its pharmaceutical division, which was caused partly by generic-drug introductions.

Shares closed Wednesday at $45.44 and were inactive premarket. The stock has risen 8% over the past year.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

React to this article
Latest news on CARDINAL HEALTH INC
08/21 CARDINAL HEALTH : Brown Applauds Department of Defense Award Recognizing Cardina..
08/14 CARDINAL HEALTH : New Cloud-Based Automation and Analytics Solutions Help Hospit..
08/12 HALOZYME THERAPEUTICS : Appoints Jeffrey W. Henderson To Board
08/10 CARDINAL HEALTH : Board Declares Dividend
08/07 CARDINAL HEALTH : SEC Receives Insider Trading Form Involving Cardinal Health
08/07 CARDINAL HEALTH : MILITARY $1.02 Billion Federal Contract Awarded to Cardinal He..
08/07 FIBROGEN : Appoints Jeffrey W. Henderson to Board of Directors
08/07 FIBROGEN : Appoints Jeffrey W. Henderson to Board of Directors
08/06 CARDINAL HEALTH : Change in Directors or Principal Officers (form 8-K)
08/06 FIBROGEN : Appoints Jeffrey W. Henderson to Board of Directors
Advertisement
Chart
Duration : Period :
Cardinal Health Inc Technical Analysis Chart | CAH | US14149Y1082 | 4-Traders
Income Statement Evolution
More Financials